JMMM Article: Using the ‘dispersion-retention-formulation method’ to estimate clinical and preclinical dosage limits for interstitial nanomedicines or agents

We propose the “DRF method” for estimating dosage limits for interstitially administered therapeutic or diagnostic nanomedicines or agents from three characteristic parameters that can be experimentally determined from in vivo data. Please see our resources section for a download of the paper and an Excel DRF calculation.

RCL-01: Magnetic Hyperthermia Agent

RCL-01RCL is proud to announce that we now have available to purchase our own high efficiency iron oxide magnetic nanoparticle specifically formulated for in vivo and in vitro magnetic hyperthermia applications. The product specification is available on our resources page. For more information about the material please contact RCL.

Horizon 2020 Project: NoCanTher

logo-completoRCL is proud to be part of a team of leading European universities, SMEs and hospitals that have recently been awarded a European Commission Horizon 2020 grant to develop a multimodal nanomedicine cancer therapy. Further information can be found on the NoCanTher website.

Hyperthermia article: Journal of Applied Physics D

IJHRCL has been working on a reliable, reproducible and accurate characterisation technique to determine the specific absorption rate (SAR) and intrinsic loss parameter (ILP) without the need for a adiabatic hyperthermia system. The paper highlights the importance for following a standardised method and demonstrates though a representative study of the literature that there exists an under/over estimation of SAR of 5% or more in over 70% of cases. The paper is due for online publication in November 2014. Excel and MATLAB scripts to calculate SAR and ILP will also be available for download from the downloads section.

European COST Action Kick-off: RADIOMAG

logo_costMultifunctional Nanoparticles for Magnetic Hyperthermia and Indirect Radiation Therapy (RADIOMAG) kicks-off early next month. The Action aims to bring together and to organise the research outcomes from the different participating network members in a practical way to provide clinicians with the necessary input to trial a novel anti-cancer treatment combining magnetic hyperthermia and radiotherapy, also identifying future research objectives upon appraisal of the obtained results. RCL is a partner on the Action and holds a substitute chair on the management committee.

CASE PhD Student

fang-yu-linRCL would like to welcome Fang-Yu Lin who will be working at RCL as part of his Doctoral training programme at UCL’s Institute of Biomedical Engineering (IBME) between 2014 and 2018. Fang-Yu will be working on developing thermal and magnetic models as part of the MAGNABLATE project.

NIHR: MAGNABLATE Project

University_College_Hospital_-_New_Building_-_London_-_020504RCL has been awarded a second grant from the National Institute for Health Research (NIHR) working in collaboration with UCL and UCH developing hyperthermia technology for magnetic thermoablation in the treatment of early prostate cancer. The project titled MAGNABLATEMAGnetic NAnoparticle ThermoABLATion – Retention and Maintenance in the prostatE, hopes to enter phase I clinical trials at the beginning of 2015.

FP7: DARTRIX Project

newsRCL has just been awarded a €600,000 grant as part of a €6 million European Commission project named DARTRIX, headed by Professor Kerry Chester from the Cancer Institute at University College London (UCL). RCL’s responsibilities within the project will be to develop cutting edge magnetic hyperthermia technology for the treatment of glioblastoma, an incurable brain cancer. Starting in 2012, the 7th Framework Programme (FP7) will aim to begin human trials late 2014/early 2015.